

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available.
Information and documents given to ASX become ASX's property and may be made public.*

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

Buddy Platform Limited

ABN

21 121 184 316

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued

(1) Fully Paid Ordinary Shares - Quoted
(2) Fully Paid Ordinary Shares - Unquoted
(3) Performance Shares (LIFX)
(4) Performance Rights (LIFX)
(5) Options - Unquoted

- 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued

(1) 4,444,444 Fully Paid Ordinary Shares - Quoted
(2) 337,794,623 Fully Paid Ordinary Shares - Unquoted
(3) 24,000,000 Performance Shares (LIFX)
(4) 24,000,000 Performance Rights (LIFX)
(5) 100,000,000 Options - Unquoted

For personal use only

Appendix 3B
New issue announcement

3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

(1) & (2) Fully Paid Ordinary Shares

(3) Performance Shares (LIFX)
Nil exercise price and vesting based on the achievement of the following milestones:

- (i) 8,000,000 (Class A) will vest upon the LIFX business contributing a cumulative A\$100 million to the Buddy Group in revenues within 18 months from 29 March 2019
- (ii) 8,000,000 (Class B) will vest upon LIFX business contributing a cumulative A\$200 million in revenues to the Buddy Group within 30 months from 29 March 2019
- (iii) 8,000,000 (Class C) will vest upon LIFX business contributing a cumulative A\$250 million in revenues to the Buddy Group within 36 months from 29 March 2019

Refer to the Notice of Meeting dated 22 February 2019, the addendum to the notice of meeting dated 18 March 2019 and the prospectus lodged on 1 April 2019 for further details.

(4) Performance Rights (LIFX)

Nil exercise price and vesting over a period of 4 years as follows:

- (i) one-quarter on the first anniversary of 29 March 2019; and
- (ii) one-sixteenth each quarter thereafter.

Refer to the Notice of Meeting dated 22 February 2019 and the addendum to the notice of meeting dated 18 March 2019.

(5) Options – exercise price of A\$0.0759 per option expiring on 01/04/2024

+ See chapter 19 for defined terms.

For personal use only

<p>4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none">• the date from which they do• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	<p>(1) & (2) Yes</p> <p>(3) & (4) No, only upon vesting into Fully Paid Ordinary Shares as disclosed in item 3.</p> <p>(5) No, only upon exercising the option into Fully Paid Ordinary Shares</p>
<p>5 Issue price or consideration</p>	<p>(1) 4,444,444 Fully Paid Ordinary Shares – Nil</p> <p>(2) 337,794,623 Fully Paid Ordinary Shares issued at A\$0.0759 per Share</p> <p>(3) 24,000,000 Performance Shares – Nil</p> <p>(4) 24,000,000 Performance Rights – Nil</p> <p>(5) 100,000,000 Options - Nil</p>

Appendix 3B
New issue announcement

For personal use only

6 Purpose of the issue
 (If issued as consideration for the acquisition of assets, clearly identify those assets)

- (1) 4,444,444 Fully Paid Ordinary Shares issued pursuant to the employment agreements entered into with Tim Peters and Marc Alexander (Shareholder approval was received at a General Meeting held on 25 March 2019, Resolutions 7 & 8)
- (2) 337,794,623 Fully Paid Ordinary Shares issued to certain minority vendors in accordance with the LIFX acquisition (Shareholder approval was received at a General Meeting held on 25 March 2019, Resolution 1)
- (3) Performance Shares
 24,000,000 Performance Shares issued in accordance with employment agreements of Marc Alexander and Tim Peters (Shareholder approval was received at a General Meeting held on 25 March 2019, Resolution 7&8)
- (4) Performance Rights
 24,000,000 Performance Rights issued in accordance with employment agreements of Marc Alexander and Tim Peters (Shareholder approval was received at a General Meeting held on 25 March 2019, Resolution 7&8)
- (5) Options
 100,000,000 options issued to the LIFX majority vendor in respect to the provision of a loan

6a Is the entity an ⁺eligible entity that has obtained security holder approval under rule 7.1A?

No

If Yes, complete sections 6b – 6h in relation to the ⁺securities the subject of this Appendix 3B, and comply with section 6i

+ See chapter 19 for defined terms.

6b	The date the security holder resolution under rule 7.1A was passed	-				
6c	Number of +securities issued without security holder approval under rule 7.1	100,000,000				
6d	Number of +securities issued with security holder approval under rule 7.1A	Nil				
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	<p>342,239,067 Fully Paid Ordinary Shares 24,000,000 Performance Shares 24,000,000 Performance Rights</p> <p>Issued in accordance with the resolutions passed by shareholders at a General Meeting held on 25 March 2019.</p>				
6f	Number of securities issued under an exception in rule 7.2	Nil				
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A				
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A				
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements	<table border="0"> <tr> <td>7.1</td> <td>150,571,160</td> </tr> <tr> <td>7.1A</td> <td>-</td> </tr> </table>	7.1	150,571,160	7.1A	-
7.1	150,571,160					
7.1A	-					
7	Dates of entering +securities into uncertificated holdings or despatch of certificates	1 April 2019				

Appendix 3B
New issue announcement

	Number	+Class
8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)	1,670,474,403	Fully Paid Ordinary Shares

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)	2,806,647	Options exercisable at \$0.10 expiring 17/11/2020
	100,000,000	Options exercisable at \$0.0759 cents expiring 01/04/2024
	4,898,503	Performance Rights
	31,833,334	Performance Shares
	15,686,354	Employee Incentive Performance Rights
	24,000,000	Performance Shares (LIFX)
	24,000,000	Performance Rights (LIFX)

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A
---	-----

Part 2 - Bonus issue or pro rata issue

- 11 Is security holder approval required?
- 12 Is the issue renounceable or non-renounceable?
- 13 Ratio in which the +securities will be offered
- 14 +Class of +securities to which the offer relates

+ See chapter 19 for defined terms.

For personal use only

- 15 +Record date to determine entitlements
- 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
- 17 Policy for deciding entitlements in relation to fractions
- 18 Names of countries in which the entity has +security holders who will not be sent new issue documents
Note: Security holders must be told how their entitlements are to be dealt with.
Cross reference: rule 7.7.
- 19 Closing date for receipt of acceptances or renunciations
- 20 Names of any underwriters
- 21 Amount of any underwriting fee or commission
- 22 Names of any brokers to the issue
- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders
- 25 If the issue is contingent on +security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled

Appendix 3B
New issue announcement

- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do +security holders sell their entitlements *in full* through a broker?
- 31 How do +security holders sell *part* of their entitlements through a broker and accept for the balance?
- 32 How do +security holders dispose of their entitlements (except by sale through a broker)?
- 33 +Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
- 36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
- 37 A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

-

For personal use only

Appendix 3B
New issue announcement

41 Reason for request for quotation now
Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)

--	--

42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)

Number	+Class

For personal use only

+ See chapter 19 for defined terms.

Quotation agreement

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.


- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



2019 Sign here:

(Company Secretary)
Stuart Usher

Date: 1 April

=====

For personal use only

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for +eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	1,072,073,287
Add the following: <ul style="list-style-type: none"> • Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2 29,912,049 • Number of fully paid ordinary securities issued in that 12 month period with shareholder approval 226,250,000 • Number of partly paid ordinary securities that became fully paid in that 12 month period 342,239,067 	
Note: <ul style="list-style-type: none"> • Include only ordinary securities here – other classes of equity securities cannot be added • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items 	
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	-
"A"	1,670,474,403

+ See chapter 19 for defined terms.

For personal use only

Step 2: Calculate 15% of "A"	
"B"	0.15 <i>[Note: this value cannot be changed]</i>
Multiply "A" by 0.15	250,571,160
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	100,000,000
"C"	100,000,000
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1	
"A" x 0.15	250,571,160
<i>Note: number must be same as shown in Step 2</i>	
Subtract "C" <i>Note: number must be same as shown in Step 3</i>	100,000,000
Total ["A" x 0.15] - "C"	150,571,160 <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
"A" <i>Note: number must be same as shown in Step 1 of Part 1</i>	-
Step 2: Calculate 10% of "A"	
"D"	0.10 <i>Note: this value cannot be changed</i>
Multiply "A" by 0.10	-
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
<p>Insert number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</p> <p><i>Notes:</i></p> <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	-
"E"	-

+ See chapter 19 for defined terms.

For personal use only

<p>Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A</p>	
<p>"A" x 0.10</p> <p><i>Note: number must be same as shown in Step 2</i></p>	-
<p>Subtract "E"</p> <p><i>Note: number must be same as shown in Step 3</i></p>	-
<p>Total ["A" x 0.10] - "E"</p>	<p>-</p> <p><i>Note: this is the remaining placement capacity under rule 7.1A</i></p>

+ See chapter 19 for defined terms.